Tinted IOL demonstrates no significant changes in contrast and sensitivity

Article

Using an ultraviolet (UV) and blue-light filtering IOL presents no significant changes in scotopic and photopic contrast sensitivity, and colour perception.

Using an ultraviolet (UV) and blue-light filtering IOL presents no significant changes in scotopic and photopic contrast sensitivity, and colour perception, according to a study published in the Journal of Cataract and Refractive Surgery.

A prospective, randomized clinical study led by Dr Marcony R. Santhiago, Ophthalmology Department, University of São Paulo, Brazil, consisted of 60 eyes of 30 patients with bilateral visually significant cataract.

Each patient was fitted with a UV and blue-light filtering IOL in one eye (Acrysof Natural SN60AT) and a UV-only IOL (Acrysof SA60AT) in the fellow eye. The primary outcome measures included scotopic and photopic contrast sensitivity, colour vision and macular findings. All measurements were taken 5 years postoperatively.

The results demonstrated no significant optical coherence tomography (OCT) findings with regards to age-related macular degeneration. Also, there were no significant differences between the groups in terms of photopic and scotopic contrast sensitivity.

Additional studies are required to identify the potential advantages of using tinted IOLs for the protection of macular cells.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.